Ivabradine (Procoralan®) has not been endorsed for use within NHS Wales for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease in combination with beta blockers in patients inadequately controlled with an optimal beta blocker dose and whose heart rate is >60bpm (licence extension). The holder of the marketing authorisation is not in a position to progress a submission to AWMSG for the appraisal of ivabradine (Procoralan®) for the above indication. As a result, AWMSG cannot provide advice to the Minister for Health and Social Services.